China Medical System Holdings Limited (HKG:0867)
14.04
-0.13 (-0.92%)
Nov 14, 2025, 4:08 PM HKT
HKG:0867 Revenue
China Medical System Holdings had revenue of 4.00B CNY in the half year ending June 30, 2025, a decrease of -13.19%. This brings the company's revenue in the last twelve months to 7.86B, up 12.06% year-over-year. In the year 2024, China Medical System Holdings had annual revenue of 7.47B, down -6.79%.
Revenue (ttm)
7.86B CNY
Revenue Growth
+12.06%
P/S Ratio
3.94
Revenue / Employee
1.28M CNY
Employees
6,141
Market Cap
33.93B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.47B | -544.30M | -6.79% |
| Dec 31, 2023 | 8.01B | -1.14B | -12.43% |
| Dec 31, 2022 | 9.15B | 813.13M | 9.75% |
| Dec 31, 2021 | 8.34B | 1.39B | 20.03% |
| Dec 31, 2020 | 6.95B | 872.34M | 14.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
China Medical System Holdings News
- 18 days ago - CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu® - GlobeNewsWire
- 3 months ago - Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease - Financial Post
- 11 months ago - Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - Benzinga